LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of “Moderate Buy” from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $100.20.

LMAT has been the subject of a number of recent research reports. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Roth Mkm reiterated a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Barrington Research restated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th.

LeMaitre Vascular Trading Up 0.5%

Shares of LMAT stock opened at $87.42 on Friday. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $105.55. The company has a 50 day moving average price of $84.53 and a 200 day moving average price of $87.66. The stock has a market capitalization of $1.98 billion, a P/E ratio of 37.68, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The company had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. During the same quarter last year, the company posted $0.49 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. Equities research analysts predict that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. Parkside Financial Bank & Trust lifted its holdings in LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares during the last quarter. Cornerstone Planning Group LLC raised its position in shares of LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares in the last quarter. MAI Capital Management purchased a new stake in LeMaitre Vascular during the third quarter worth approximately $38,000. First Horizon Corp acquired a new position in LeMaitre Vascular in the third quarter valued at approximately $39,000. Finally, Geneos Wealth Management Inc. increased its stake in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.